Analysts Are Gushing Over Amdocs Limited (DOX), Incyte Corporation (INCY)

Amdocs Limited (NASDAQ:DOX) last session’s volume of 0.98 million shares was higher than its average volume of 0.86 million shares. The stock, after opening at $66.88, hit $64.47 through the close by scoring -4.43%.

Amdocs Limited (DOX) Analyst Opinion

Amdocs Limited has a consensus outperform rating from 7 Wall Street analysts, and the number of shares currently sold short amount to at least 1.55% of shares outstanding. The stock sank -3.42% last month and is down -1.54 this year. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover DOX having a buy-equivalent rating. Analysts have placed a $73.75 price target on Amdocs Limited, suggesting a 14.39% gain from recent close. It’s currently trading about -9.67% below its 52-week high.

Amdocs Limited Earnings Surprise

Amdocs Limited (DOX) surprised the stock market in its last reported earnings when it earned $1.06 a piece versus the consensus-estimated $0.97. Its revenue totaled $979.32 million down -0.04% from the previous quarter.

Amdocs Limited (NASDAQ:DOX) Intraday View

This stock (DOX) is ahead of its 52-week low with 14.91%. Its last month’s stock price volatility remained 2.69% which for the week stands at 1.56%. The share price has moved backward from its 20 days moving average, trading at a distance of -5.8% and stays -3.16% away from its 50 days moving average. Over the last five days, shares have faced -7.42% losses and now is down -0.59% since hitting its 200-day moving average of $65.31. Amdocs Limited (DOX) has made its way to a 12-month gain of 8.74%.

Turning to Incyte Corporation (NASDAQ:INCY), its shares were trading at $85.34 a retreat of $-0.58, on the trading floor. The stock, after opening at $86.09, touched a high of $87.9 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Incyte Corporation has 5 buy ratings, 4 holds and 0 sells even after the stock tumbled -44.28% from its high of $153.15 to a $18.8 billion market value through last close.

Incyte Corporation (INCY) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.95 to 1.95 during a month. Analysts set a 12-month price target of $142.47 a share. The target implies a 66.94% spike from where the shares are currently trading. Also, the current price highlights a discount of 102.72% to analysts’ high consensus price target.

Incyte Corporation (NASDAQ:INCY) Intraday Trading

The counter witnessed a trading volume of 2.34 million shares versus an average volume of 1.63 million shares during last trading session. Its last month’s stock price volatility remained 2.96% which for the week approaches 2.97%. The lowest price the stock reached in the last trading day was $85.31 and compares with the $85.75 52-week low. The stock recovered -0.48% since its low point and has performed -9.89% year-to-date.

SHARE
Previous articleAnalysts Give These Stocks Mix Nod: Lattice Semiconductor Corporation (LSCC), Axovant Sciences Ltd. (AXON)
Next articleStreet Analysts View On Vulcan Materials Company (VMC), Idera Pharmaceuticals, Inc. (IDRA)